Drug Approval | September 06, 2021
Accutest enables NMPA approval for Qilu’s Abiraterone
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
The trial will be conducted across 10 sites in India
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Invega Hafyera offers patients the fewest doses per year. Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months
The vaccine is designed to neutralise the virus in the nostril itself and prevent it from penetrating deep down into the respiratory tract
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
The facility has the capacity to produce one crore doses per day
Subscribe To Our Newsletter & Stay Updated
